Senores Pharmaceuticals, a rapidly growing pharmaceutical company, is all set to launch its IPO, offering a Book Built Issue totaling ₹582.11 Crores. The Fresh Issue includes 127.87 lakh shares worth ₹500.00 Crores, and the Offer for Sale comprises 21.00 lakh shares totaling ₹82.11 Crores. This IPO marks an important milestone for the company, which focuses on manufacturing complex and specialty pharmaceuticals for the regulated markets of the US, Canada, and the UK, as well as emerging markets.

The IPO price band has been set between ₹372 and ₹391 per equity share. The lot size for retail investors is 38 shares, with a minimum investment of ₹14,858. High-Net-Worth Individuals (HNIs) must apply for a minimum of 14 lots, totaling ₹208,012.

The IPO subscription period opens on December 20, 2024, and closes on December 24, 2024. Allotment is expected by December 26, 2024, with the shares listed on BSE and NSE around December 30, 2024.

Grey Market Premium and Subscription Updates:

As of December 23, 2024, the Grey Market Premium (GMP) for Senores Pharmaceuticals IPO stands at ₹156, indicating a 39.95% premium. The company’s strong financial performance and investor confidence have contributed to this positive outlook.

The IPO was subscribed 5.85 times on its second day of the subscription period, indicating robust demand from investors.

Senores Pharmaceuticals IPO Objective and Fund Utilization:

The company intends to utilize the funds raised through the IPO for various strategic objectives:

1. Investment in its subsidiary, Havix Group (Aavis Pharmaceuticals), for setting up a sterile injection manufacturing facility in Atlanta.
2. Repayment of borrowings for both the company and its subsidiaries.
3. Funding working capital requirements to support operational growth.
4. Inorganic growth through acquisitions and strategic initiatives to strengthen its market position.

Financial Performance:

Senores Pharmaceuticals has demonstrated impressive financial growth, with revenues increasing from ₹146.31 million in FY2022 to ₹1,833.53 million in FY2024. The EBITDA and Profit after Tax (PAT) have similarly shown strong growth. For FY2024, PAT stood at ₹239.43 million, reflecting a steady upward trajectory.

Key Metrics:

• Pre-issue EPS: ₹12.21
• Post-issue EPS: ₹7.10
• Pre-issue P/E ratio: 32.02x
• Post-issue P/E ratio: 55.05x (compared to the industry P/E ratio of 39x)
• ROCE: 11.73%
• ROE: 23.60%

Given these strong financials and the Grey Market Premium, investors are likely to see a potential listing gain from this IPO. The company's strategic initiatives and market growth prospects further enhance its appeal to investors.

The Upcoming IPOs in this week and coming weeks are Solar91 Cleantech, Anya Polytech, Rosmerta Digital, Indo Farm, and Avanse Financial. The Current active IPO is Unimech Aerospace, Ventive Hospitality, Senores Pharmaceuticals, Carraro India, Transrail Lighting, Mamata Machinery, DAM Capital, Sanathan Textiles, Concord Enviro and Newmalayan Steel. For more details on upcoming IPOs, you can visit our page at  and stay updated with the latest news on IPO updates on . Join our  for regular Stock Market Trading and Investment Calls by  - SEBI Registered Research Analyst &  for Regular Share Market, News & IPO Updates. Start your Stock Market Journey and Apply in IPO by opening a Free Demat Account in .Best IPO to Apply Now - IPO List 2024, Latest IPO, Upcoming IPO, Recent IPO News, Live IPO GMP Today - Finance SaathiTop News Headlines - Share Market News, Latest IPO News, Business News, Economy News - Finance SaathiTrading with CA Abhay Telegram ChannelCA Abhay VarnFinance Saathi Telegram ChannelChoice Broking FinX.